Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial

Michael R. Liebowitz, Hollander Eric, Schneier Frank, Campeas Raphael, Hatterer Julie, Papp Laszlo, Fairbanks Janet, Sandberg Diana, Davies Sharon, Stein Maria

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessivecompulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62% (24/39) of adequately treated patients and 49% (24/49) of the whole sample. These uncontrolled findings suggest that fluoxetine is of significant benefit for a substantial proportion of obsessive-compulsive disorder patients. However, controlled trials comparing fluoxetine with placebo and other active agents are needed to confirm this, as are studies aimed to delineate fluoxetine’s full dose range, optimal length of treatment and relapse rate following discontinuation.

Original languageEnglish (US)
Pages (from-to)423-427
Number of pages5
JournalJournal of Clinical Psychopharmacology
Issue number6
StatePublished - Dec 1989
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial'. Together they form a unique fingerprint.

Cite this